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Aims: Burkholderia pseudomallei, the human pathogen that causes melioidosis, is intrinsically resistant towards a wide 
range of antibiotics and there have been reports of acquired resistance towards antibiotics used for melioidosis 
treatments. Antimicrobial peptides (AMP) such as bacteriocins are gaining the interests of researchers as alternative for 
treating infections caused by multidrug resistant bacteria. In this study, we aimed to identify Burkholderia spp. isolated 
from soil in Sarawak that possess the potential in inhibiting the growth of B. pseudomallei and to further characterize the 
antagonistic compound produced. 
Methodology and results: A total of 50 Burkholderia spp. isolates of environmental origin and two isolates of Ralstonia 
solanacearum were screened against five clinical isolates of B. pseudomallei using spot-on-lawn assay and flip streak 
method. Burkholderia stagnalis isolate K23/3 showed clear zones of inhibition (ZOI) in both preliminary tests. Cell-free 
supernatant (CFS) was obtained from B. stagnalis K23/3 broth culture and was tested via agar well diffusion assay 
(AWDA). The antagonistic compound secreted at the early log phase of the bacterial growth was shown to be stable in a 
wide range of temperatures and pH. Treatment with different enzymes revealed that it was sensitive towards proteinase 
K, suggesting that it is proteinaceous. The bacteriocin-like-substance (BLIS) was subjected to ammonium sulfate 
precipitation and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The SDS-PAGE gel was 
overlaid with indicator B. pseudomallei isolates where the active protein was shown to be less than 7.1 kDa. 
Conclusion, significance and impact of study: Burkholderia stagnalis isolate K23/3 was able to secrete bacteriocin-
like-substance (BLIS) that has the potential in biocontrol of B. pseudomallei in the environment or as potential treatment 
for melioidosis. 
 




Melioidosis is a potentially fatal infectious disease that is 
caused by the bacterium Burkholderia pseudomallei. With 
ineffective antimicrobial treatment, the fatality rate of 
melioidosis is expected to exceed 70% (Limmathurotsakul 
et al., 2016), making it a life-threatening infectious 
disease. Melioidosis has been recognized as one of the 
important human infections in Malaysia (Nathan et al., 
2018), Singapore and across the north of Australia 
(White, 2003) and Southeast Asia (Limmathurotsakul et 
al., 2016). Over the past years, this disease has been 
emerging in tropical developing countries that were not 
previously reported such as Africa (Birnie et al., 2015), 
Puerto Rico (Doker et al., 2015) and Brazil (Rolim et al., 
2018). A person could be infected by B. pseudomallei 
through inhalation, open wound inoculation or ingestion of 
contaminated environmental sources (Barnes and 
Ketheesan, 2005). According to Currie et al. (2000), the 
incubation period for melioidosis is estimated to be 1–21 
days and may extend to months and even years. It is 
influenced by the amount of inoculum, route of infection 
and underlying host risk factors (Ngauy et al., 2005).  
However, B. pseudomallei has the tendency of staying 
dormant in humans for a prolonged period (Wiersinga et 
al., 2012). 
Burkholderia pseudomallei is intrinsically resistant to 
many classes of commonly used antibiotics such as β-
lactams, aminoglycosides, macrolides and 
fluoroquinolones (Lipsitz et al., 2012). Currently, 
meropenem, trimethoprim/sulfamethoxazole (TMP-SMX) 
and doxycycline are used for melioidosis treatment 
(Dance, 2014). However, there were reported possible 
resistance towards TMP-SMX (Wuthiekanun et al., 2005; 
Yong et al., 2016) and meropenem (Yong et al., 2016). 
Although yet to be verified through comprehensive in-
depth studies, concerns of possible resistance towards 
antibiotics is a major concern to the public health. Thus, 
